{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:02:15Z","timestamp":1762430535192},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,3,5]],"date-time":"2011-03-05T00:00:00Z","timestamp":1299283200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00198-011-1593-2","type":"journal-article","created":{"date-parts":[[2011,3,6]],"date-time":"2011-03-06T09:37:11Z","timestamp":1299404231000},"page":"339-349","source":"Crossref","is-referenced-by-count":38,"title":["Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys"],"prefix":"10.1007","volume":"23","author":[{"given":"C.","family":"Jerome","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Missbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gamse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,5]]},"reference":[{"key":"1593_CR1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1590\/S0004-27302006000400020","volume":"50","author":"JL Borges","year":"2006","unstructured":"Borges JL, Bilezikian JP (2006) Update on osteoporosis therapy. Arq Bras Endocrinol Metabol 50:755\u2013763","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"1593_CR2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2165\/00024677-200605060-00003","volume":"5","author":"M Girotra","year":"2006","unstructured":"Girotra M, Rubin MR, Bilezikian JP (2006) Anabolic agents for osteoporosis: what is their likely place in therapy? Treat Endocrinol 5:347\u2013358","journal-title":"Treat Endocrinol"},{"key":"1593_CR3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1590\/S0004-27302006000400018","volume":"50","author":"M McClung","year":"2006","unstructured":"McClung M (2006) Bisphosphonates. Arq Bras Endocrinol Metabol 50:735\u2013744","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"1593_CR4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.clinthera.2006.02.007","volume":"28","author":"S Epstein","year":"2006","unstructured":"Epstein S (2006) Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 28:151\u2013173","journal-title":"Clin Ther"},{"key":"1593_CR5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/14740338.1.1.71","volume":"1","author":"JK Marshall","year":"2002","unstructured":"Marshall JK (2002) The gastrointestinal tolerability and safety of oral bisphosphonates. Exp Opin Drug Safety 1:71\u201378","journal-title":"Exp Opin Drug Safety"},{"key":"1593_CR6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00198-005-1957-6","volume":"17","author":"JY Reginster","year":"2006","unstructured":"Reginster JY, Felsenberg D, Cooper C, Stakkestad JA, Miller PD, Kendler DL, Adami S, McClung MR, Bolognese MA, Civitelli R, Dumont E, Bonvoisin B, Recker RR, Delmas PD (2006) A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporos Int 17:159\u2013166","journal-title":"Osteoporos Int"},{"key":"1593_CR7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bone.2005.11.013","volume":"38","author":"JY Reginster","year":"2006","unstructured":"Reginster JY (2006) Adherence and persistence: impact on outcomes and health care resources. Bone 38:18\u201321","journal-title":"Bone"},{"key":"1593_CR8","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1359\/jbmr.060712","volume":"21","author":"E Shane","year":"2006","unstructured":"Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S, Pendrys D (2006) Osteonecrosis of the jaw: more research needed. J Bone Miner Res 21:1503\u20131505","journal-title":"J Bone Miner Res"},{"key":"1593_CR9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1196\/annals.1346.042","volume":"1068","author":"BF Boyce","year":"2006","unstructured":"Boyce BF, Xing L, Yao Z, Shakespeare WC, Wang Y, Metcalf CA 3rd, Sundaramoorthi R, Dalgarno DC, Iuliucci JD, Sawyer TK (2006) Future anti-catabolic therapeutic targets in bone disease. Ann NY Acad Sci 1068:447\u2013457","journal-title":"Ann NY Acad Sci"},{"key":"1593_CR10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/B978-012098652-1.50109-8","volume-title":"Principles of bone biology","author":"N Takahashi","year":"2002","unstructured":"Takahashi N, Udagawa M, Takami M, Suda T (2002) Cells of bone: osteoclast generation. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology, 2nd edn. Academic, San Diego, pp 109\u2013126","edition":"2"},{"key":"1593_CR11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/B978-012098652-1.50110-4","volume-title":"Principles of bone biology","author":"K V\u00e4\u00e4n\u00e4nen","year":"2002","unstructured":"V\u00e4\u00e4n\u00e4nen K, Zhao H (2002) Osteoclast function: biology and mechanism. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology, 2nd edn. Academic, San Diego, pp 127\u2013139","edition":"2"},{"key":"1593_CR12","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.addr.2004.12.013","volume":"57","author":"Y Yasuda","year":"2005","unstructured":"Yasuda Y, Kaleta J, Bromme D (2005) The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 57:973\u2013993","journal-title":"Adv Drug Deliv Rev"},{"key":"1593_CR13","doi-asserted-by":"crossref","first-page":"12511","DOI":"10.1074\/jbc.271.21.12511","volume":"271","author":"FH Drake","year":"1996","unstructured":"Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaczewski E, Coleman L, Rieman D, Barthlow R, Hastings G, Gowen M (1996) Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 271:12511\u201312516","journal-title":"J Biol Chem"},{"key":"1593_CR14","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1359\/jbmr.1999.14.10.1654","volume":"14","author":"M Gowen","year":"1999","unstructured":"Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, Bertoncello I, Drake F, Zavarselk S, Tellis I, Hertzog P, Debouck C, Kola I (1999) Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 14:1654\u20131663","journal-title":"J Bone Miner Res"},{"key":"1593_CR15","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.1073\/pnas.95.23.13453","volume":"95","author":"P Saftig","year":"1998","unstructured":"Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, von Figura K (1998) Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 95:13453\u201313458","journal-title":"Proc Natl Acad Sci USA"},{"key":"1593_CR16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0968-0896(99)00011-5","volume":"7","author":"RW Marquis","year":"1999","unstructured":"Marquis RW, Ru Y, Yamashita DS, Oh HJ, Yen J, Thompson SK, Carr TJ, Levy MA, Tomaszek TA, Ijames CF, Smith WW, Zhao B, Janson CA, Abdel-Meguid SS, D'Alessio KJ, McQueney MS, Veber DF (1999) Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K. Bioorg Med Chem 7:581\u2013588","journal-title":"Bioorg Med Chem"},{"key":"1593_CR17","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1359\/jbmr.1997.12.9.1396","volume":"12","author":"BJ Votta","year":"1997","unstructured":"Votta BJ, Levy MA, Badger A, Bradbeer J, Dodds RA, James IE, Thompson S, Bossard MJ, Carr T, Connor JR, Tomaszek TA, Szewczuk L, Drake FH, Veber DF, Gowen M (1997) Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J Bone Miner Res 12:1396\u20131406","journal-title":"J Bone Miner Res"},{"key":"1593_CR18","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1359\/jbmr.2001.16.10.1739","volume":"16","author":"GB Stroup","year":"2001","unstructured":"Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S, Dare LC, Erhard KF, Hoffman SJ, James IE, Marquis RW, Ru Y, Vasko-Moser JA, Smith BR, Tomaszek T, Gowen M (2001) Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 16:1739\u20131746","journal-title":"J Bone Miner Res"},{"key":"1593_CR19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2006.07.015","volume":"40","author":"S Kumar","year":"2007","unstructured":"Kumar S, Dare L, Vasko-Moser JA, James IE, Blake SM, Rickard DJ, Hwang SM, Tomaszek T, Yamashita DS, Marquis RW, Oh H, Jeong JU, Veber DF, Gowen M, Lark MW, Stroup G (2007) A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 40:122\u2013131","journal-title":"Bone"},{"issue":"4","key":"1593_CR20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00223-009-9279-x","volume":"85","author":"GB Stroup","year":"2009","unstructured":"Stroup GB, Kumar S, Jerome CP (2009) Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys. Calcif Tissue Int 85(4):344\u2013355","journal-title":"Calcif Tissue Int"},{"issue":"Suppl 1","key":"1593_CR21","first-page":"S251","volume":"20","author":"M Missbach","year":"2005","unstructured":"Missbach M, Altmann E, Betschart C, Buhl T, Gamse R, Gasser JA, Green JR, Ishihara H, Jerome C, Kometani M, Susa M, Teno N, Toriyama K, Lattmann R (2005) AAE581, a potent and highly specific cathepsin K inhibitor, prevents bone resorption after oral treatment in rat and monkey. J Bone Miner Res 20(Suppl 1):S251","journal-title":"J Bone Miner Res"},{"key":"1593_CR22","first-page":"618","volume":"48","author":"CP Jerome","year":"1998","unstructured":"Jerome CP (1998) Primate models of osteoporosis. Lab Anim Sci 48:618\u2013622","journal-title":"Lab Anim Sci"},{"issue":"199","key":"1593_CR23","first-page":"208","volume":"39","author":"K Bayne","year":"1996","unstructured":"Bayne K (1996) Revised guide for the care and use of laboratory animals available. Am Physiol Society Physiologist 39(199):208\u2013211","journal-title":"Am Physiol Society Physiologist"},{"key":"1593_CR24","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","volume":"2","author":"AM Parfitt","year":"1987","unstructured":"Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595\u2013610","journal-title":"J Bone Miner Res"},{"key":"1593_CR25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S8756-3282(97)00008-2","volume":"20","author":"CP Jerome","year":"1997","unstructured":"Jerome CP, Power RA, Obasanjo IO, Register TC, Guidry M, Carlson CS, Weaver DS (1997) The androgenic anabolic steroid nandrolone decanoate prevents osteopenia and inhibits bone turnover in ovariectomized cynomolgus monkeys. Bone 20:355\u2013364","journal-title":"Bone"},{"key":"1593_CR26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S8756-3282(00)00430-0","volume":"28","author":"CP Jerome","year":"2001","unstructured":"Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R (2001) Treatment with human parathyroid hormone (1\u201334) for 18\u00a0months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28:150\u2013159","journal-title":"Bone"},{"key":"1593_CR27","unstructured":"Cusik T, Pennypacker B, Scott K, Duong L, Kimmel D (2009) Effects of odanacatib on bone mass, turnover and strength in the femoral neck of estrogen deficient adult rhesus monkeys. J Bone Miner Res 24(Suppl 1). Available at http:\/\/www.asbmr.org\/Meetings\/AnnualMeeting\/AbstractDetail.aspx?aid=3c062e5c-74c9-4be1-b2c9-2935ae73f57e . Accessed June 1, 2010"},{"key":"1593_CR28","unstructured":"Pennypacker B, Wesolowski G, Heo J, Duong L (2009) Effects of odanacatib on central femur cortical bone in estrogen deficient adult rhesus monkeys. J Bone Miner Res 24(Suppl 1). Available at http:\/\/www.asbmr.org\/Meetings\/AnnualMeeting\/AbstractDetail.aspx?aid=a11932a7-b4c2-4d38-9a9d-4ec165bb13f2 . Accessed June 1, 2010"},{"issue":"5","key":"1593_CR29","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.bone.2007.01.010","volume":"40","author":"A Xiang","year":"2010","unstructured":"Xiang A, Kanematsu M, Kumar S, Yamashita D, Kaise T, Kikkawa H, Asano S, Kinoshita M (2010) Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice. Bone 40(5):1231\u20131237","journal-title":"Bone"},{"key":"1593_CR30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/00042192-200209000-00004","volume":"9","author":"CJ Lees","year":"2002","unstructured":"Lees CJ, Register TC, Turner CH, Wang T, Stancill M, Jerome CP (2002) Effects of raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys. Menopause 9:320\u2013328","journal-title":"Menopause"},{"issue":"1","key":"1593_CR31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bone.2009.10.023","volume":"46","author":"A Feher","year":"2010","unstructured":"Feher A, Koivunemi A, Koivunemi M, Fuchs RK, Burr DB, Phipps RJ, Reinwald S, Allen MR (2010) Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading. Bone 46(1):203\u2013207","journal-title":"Bone"},{"issue":"Suppl 1","key":"1593_CR32","first-page":"SA414","volume":"20","author":"S Bare","year":"2005","unstructured":"Bare S, Recker S, Recker R, Kimmel D (2005) Influence of alendronate on periosteal and endocortical bone formation in the ilium of osteoporotic women. J Bone Miner Res 20(Suppl 1):SA414, Available at http:\/\/www.abstractsonline.com\/viewer\/viewAbstractPrintFriendly.asp?CKey={320D85D2-5D21-4529-A15C-8B342938C99F}&SKey={BEF5BC3E-1AC0-489B-A7FB-6F4FC82D96B1}&MKey={70A6304C-A41B-49FC-A4DF-C147A5E943F0}&AKey={D0C01D4F-E23B-45E2-ACD4-0AF8AC866B8B }. Accessed June 10, 2010","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1593_CR33","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","volume":"15","author":"T Mashiba","year":"2000","unstructured":"Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15(4):613\u2013620","journal-title":"J Bone Miner Res"},{"issue":"Suppl. 1","key":"1593_CR34","first-page":"S24","volume":"21","author":"A Itabashi","year":"2006","unstructured":"Itabashi A, Kurata N, Sugita Y, Kawai Y (2006) Balicatib, a novel cathepsin K-inhibitor, increases serum intact PTH beyond diurnal patterns following 14-daily administration in Japanese postmenopausal women. J Bone Miner Res 21(suppl 1):S24","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1593_CR35","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bone.2007.09.044","volume":"42","author":"K Fuller","year":"2008","unstructured":"Fuller K, Lawrence KM, Ross JL, Grabowska UB, Shiroo M, Samuelsson B, Chambers TJ (2008) Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone 42(1):200\u2013211","journal-title":"Bone"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-011-1593-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-011-1593-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-011-1593-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:08:37Z","timestamp":1558609717000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-011-1593-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,5]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1593"],"URL":"https:\/\/doi.org\/10.1007\/s00198-011-1593-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"type":"print","value":"0937-941X"},{"type":"electronic","value":"1433-2965"}],"subject":[],"published":{"date-parts":[[2011,3,5]]}}}